The ACCOST-HH Trial: An investigator-initiated trial, the placebo-controlled, double-blind, multi-centre, randomized trial to assess the efficacy and safety of the antibody AdreCizumab (HAM8101) against plaCebO in SubjecTs witH cardiogenic sHock, (ACCOST-HH) in progress is discussed

The ACCOST-HH Trial

PubMed	33111142

Sitemap | Datenschutz | Impressum Universitätsklinikum Hamburg-Eppendorf